Cardiac Safety: Key issues and best practice for Thorough QT Studiesand Intensive Phase I QT Studies~ A specialist workshop sponsored by Richmond Pharmacology ~

As collaborating sponsors of the joint AMIFE IFAPP 16th International Conference on Pharmaceutical Medicine � ICPM 2012, Richmond Pharmacology welcomes attendees to join its specialist workshop on Day 2, 15 Nov exploring �Cardiac Safety: Key issues and best practice for Thorough QT Studies and Intensive Phase I QT Studies�.Co-chaired by the internationally acclaimed experts Beno�t Tyl, Georg Ferber and Jorg Taubel, the workshop will look at the biological background to the ICH E14 guidance. They will present the rationale of the thorough QT study and discuss the key elements of a state of the art design and analysis of such a study. The second half of the workshop will address the placement of the TQT study in clinical development and give an update on current CSRC discussions and on conditions under which regulators may be likely to waive a TQT study at present and in future.Attendees are encouraged to submit questions or current problems they may wish the panel to address during the roundtable discussions in advance to:info@richmondpharmacology.comView ICPM 2012 Scientific ProgramRegister for this conference

Latest news

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Patient with rare bleeding disorder becomes first to test new treatment

May 22, 2024
The thousands of patients who participate in Richmond’s trials are helping to advance medical science and save lives and, in the process, some make history. In a film released today, one trial participant tells her story.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event